CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...